These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 30733081)
21. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215 [TBL] [Abstract][Full Text] [Related]
22. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic. Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125 [TBL] [Abstract][Full Text] [Related]
23. Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer. Tea MK; Kroiss R; Muhr D; Fuerhauser-Rappaport C; Oefner P; Wagner TM; Singer CF Maturitas; 2014 Jan; 77(1):68-72. PubMed ID: 24156927 [TBL] [Abstract][Full Text] [Related]
24. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035 [TBL] [Abstract][Full Text] [Related]
25. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P; Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744 [TBL] [Abstract][Full Text] [Related]
26. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position? Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665 [TBL] [Abstract][Full Text] [Related]
27. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Gonzalez-Hormazabal P; Gutierrez-Enriquez S; Gaete D; Reyes JM; Peralta O; Waugh E; Gomez F; Margarit S; Bravo T; Blanco R; Diez O; Jara L Breast Cancer Res Treat; 2011 Apr; 126(3):705-16. PubMed ID: 20859677 [TBL] [Abstract][Full Text] [Related]
28. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077 [TBL] [Abstract][Full Text] [Related]
29. Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer. Rump A; Benet-Pages A; Schubert S; Kuhlmann JD; Janavičius R; Macháčková E; Foretová L; Kleibl Z; Lhota F; Zemankova P; Betcheva-Krajcir E; Mackenroth L; Hackmann K; Lehmann J; Nissen A; DiDonato N; Opitz R; Thiele H; Kast K; Wimberger P; Holinski-Feder E; Emmert S; Schröck E; Klink B PLoS Genet; 2016 Aug; 12(8):e1006248. PubMed ID: 27504877 [TBL] [Abstract][Full Text] [Related]
30. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930 [TBL] [Abstract][Full Text] [Related]
31. Inherited Mutations in Women With Ovarian Carcinoma. Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728 [TBL] [Abstract][Full Text] [Related]
32. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception. Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C; J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436 [TBL] [Abstract][Full Text] [Related]
34. [Breast cancer susceptibility genes]. Díez O; Gutiérrez-Enríquez S; Ramón y Cajal T Med Clin (Barc); 2006 Mar; 126(8):304-10. PubMed ID: 16527158 [TBL] [Abstract][Full Text] [Related]
35. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. Fostira F; Kostantopoulou I; Apostolou P; Papamentzelopoulou MS; Papadimitriou C; Faliakou E; Christodoulou C; Boukovinas I; Razis E; Tryfonopoulos D; Barbounis V; Vagena A; Vlachos IS; Kalfakakou D; Fountzilas G; Yannoukakos D J Med Genet; 2020 Jan; 57(1):53-61. PubMed ID: 31300551 [TBL] [Abstract][Full Text] [Related]
36. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling. Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859 [TBL] [Abstract][Full Text] [Related]
37. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Tonin PN Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226 [TBL] [Abstract][Full Text] [Related]
39. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591 [TBL] [Abstract][Full Text] [Related]
40. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]